Print

Isomark, a Startup for Early Sepsis Detection Hopes for New CEO and 2014 Market Launch  
11/5/2012 8:32:53 AM

Isomark, a Wisconsin, Madison-based medical device company, was founded back in 2005 with a goal to commercialize a technology developed at the University of Wisconsin-Madison that could detect blood infections early. But lacking a focus on what market to pursue meant the company didn’t really start to raise money until 2010. That occurred shortly before Dave Kruse, currently interim CEO, came on board when the company decided it should focus on adults and children who are in the hospital and breathing with the assistance of a ventilator. Kruse first raised $300,000 in an angel round followed by $130,000 in a bridge round. Now with a clinical trial complete, Isomark is hoping to hire a new CEO by the end of the year and raise a little over $1 million, all with the goal of launching the sepsis detection device in late 2014. Severe sepsis is estimated to affect 750,000 people annually in the U.S. and the infection has a 28.6 percent mortality rate. It kills more people than stroke and pneumonia.
//-->